HomeAGIO • NASDAQ
Follow
Agios Pharmaceuticals Inc
Previous close
$29.51
Day range
$28.73 - $29.80
Year range
$19.80 - $35.50
Market cap
1.64B USD
Avg Volume
661.51K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 7.10M | 64.80% |
Operating expense | 35.30M | 7.73% |
Net income | -95.94M | -362.66% |
Net profit margin | -1.35K | -259.38% |
Earnings per share | -1.72 | -3.35% |
EBITDA | -104.87M | -7.72% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 776.93M | -0.79% |
Total assets | 937.12M | -24.35% |
Total liabilities | 126.10M | -8.56% |
Total equity | 811.02M | — |
Shares outstanding | 56.19M | — |
Price to book | 2.04 | — |
Return on assets | -27.33% | — |
Return on capital | -28.80% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -95.94M | -362.66% |
Cash from operations | -72.49M | -9.56% |
Cash from investing | 95.51M | 15.14% |
Cash from financing | 847.00K | 3,750.00% |
Net change in cash | 23.87M | 42.01% |
Free cash flow | -42.30M | -30.47% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
385
